It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Looking for ways to earn cash fast at home for free? Check out these straightforward methods to get your finances on track quickly.
22,290 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Two leading firms cut Microsoft price targets ahead of fiscal Q4, but both retain bullish ratings as Copilot and Azur...
An unexpected move by Etsy’s board member sparked questions about insider trading activity. This article breaks down ...
A regulatory hint sent Moderna stock just popped, but the journey from acceptance to approval matters. This guide bre...
A quarterly data snapshot reveals moves by the wealthiest fund managers. This piece dives into why these billionaire ...
A major partnership reshapes Novo Nordisk's growth trajectory. This deep dive explains what the Vivtex deal means for...
Moderna and Ross Stores surged midweek on distinct catalysts: a patent settlement clearing a key overhang for Moderna...
A fresh take on a notable portfolio move: Kettle Hill Capital reveals a sizable Braze stake via a 747,715-share initi...
Quantum computing could reshape many industries, but is IonQ stock your ticket to millionaire status? This guide expl...
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Palantir often looks pricey at first glance, but the real story may be hidden in growth engines and future contracts....
Volatile markets test an investor’s nerves and resolve. The key to thriving, not just surviving, is focusing on a dis...